GCM
RXDX

Graham Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Graham Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-23,294
Closed -$657K – 1387
2022
Q2 		$657K Buy
+23,294
New +$675K 0.03% 578

Other funds holding RXDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Graham Capital Management's RXDX Position: Q3 2022 in Review

Graham Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q3 2022, closing a stake of 23,294 shares — an estimated $657K sold.

Graham Capital Management first reported a position in RXDX in Q2 2022 and held it in 1 quarter. The position peaked at $657K in Q2 2022. 144 funds tracked by Wall St. Rank hold RXDX as of Q3 2022.

  • Graham Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Graham Capital Management sold 23,294 Prometheus Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $657K.
  • Graham Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Graham Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $657K in Q2 2022.
  • 144 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q3 2022.

Based on Graham Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.